Motif Bio performs less than average in Research & Development when compared to other small and medium-sized enterprises in scope.
Motif Bio has four antibacterial projects for priority pathogens in its pipeline. It commits to developing access plans for its late-stage projects to address affordability in access countries.
Sales & Operations
Sales & Operations
Therapeutic areas: Multidrug-resistant Gram-positive bacteria Products on the market: None R&D grants received since 2016: At least USD 120,000, awarded from one funder (Cystic Fibrosis Foundation). This award was granted in January 2018 to fund in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis. Financing and Investment Structure: Motif Bio is a publicly listed company. It completed its IPO in November 2016 on the NASDAQ stock exchange, raising USD 25 million. It is also listed on the London Stock Exchange. M&A since 2018: None in the antibacterial and/or antifungal sectors
Pipeline & Portfolio
for diseases in scope
Pipeline size: 4 projects for priority pathogens* (4 antibacterial medicines) Development stages: 2 clinical projects for iclaprim, for the treatment of acute bacterial skin and skin structure infections and hospital-acquired and ventilator-associated bacterial pneumonia, and 2 pre-clinical projects Novelty: No novel clinical-stage medicine projects Regulatory approvals: 0 approvals for priority pathogens Access plans: 2 of 2 late-stage R&D projects with project-specific access plans, both of which are commitments to develop equitable pricing strategies in low- and middle-income countries, as well as to target registration based on public health need and disease prevalence Stewardship plans: Neither of its 2 late-stage R&D medicine projects have project-specific stewardship plans.
Opportunities for Motif Bio
Operationalise stewardship plans for iclaprim. Motif Bio is developing one antibacterial candidate (iclaprim) in late-stage clinical development. Motif Bio can develop specific plans to ensure that iclaprim will be appropriately used globally after market approval. As examples of stewardship plans, the company can commit to decouple sales incentives from sales volumes and/or become involved in antibacterial surveillance activities.
Changes since 2018
Changes since 2018
Announced a partnership with the NIH in August 2019 to evaluate iclaprim activity against L. monocytogenes.
Required by the FDA in June 2019 to conduct further study of iclaprim to evaluate potential risk of elevated transaminases.
Performance by research area
Indicators scored on
Research & Development
Evaluated: medicine & vaccine pipelines for priority* bacteria & fungi
A.1 R&D investments Motif Bio invested USD 40.5 million in the development of antibacterial medicines in 2017 and 2018. As with all other SMEs evaluated, Motif Bio was not scored in this indicator.
A.2.1 Pipeline size of four projects Motif Bio reports four projects targeting priority pathogens in its pipeline. The company focuses on antibacterial medicine development, and has two projects in pre-clinical development and two in Phase III of clinical development. One of these projects has been submitted for market approval.
A.2.2 No clinical-stage novel projects Motif Bio’s clinical-stage medicine pipeline for priority pathogens consists of both new and adapted R&D projects. It does not currently include candidates that are considered novel. However, Motif Bio is developing iclaprim for the treatment of acute bacterial skin and skin structure infections, as well as hospital-acquired and ventilator-associated pneumonia.
A.2.3 Vaccines in the pipeline Motif Bio is not eligiblefor this indicator as it is not active in vaccine development.
A.2.4 No candidates targeting critical and/or urgent priorities Motif Bio does not have any candidate targeting pathogens considered ‘critical’ and/or ‘urgent’ R&D priorities for limiting AMR, as defined by WHO and/or the US Centers for Disease Control and Prevention (CDC).
A.3 Intellectual capital sharing As an SME, Motif Bio was not scored for this indicator, in line with the external stakeholder consensus defined by the Foundation.
A.4 Commits to addressing access for 2 of 2 projects; no stewardship plans Motif Bio has committed to addressing affordability for its two late-stage R&D projects targeting priority pathogens. The company commits to filing iclaprim for registration based on public health needs and disease prevalence. It also commits to addressing the affordability of its products in low- and middle-income countries with pricing strategies that take affordability into account. The company makes a general commitment to improving stewardship but does not provide details on stewardship programmes.
Pipeline targeting priority pathogens: 4
As a small- to medium-sized enterprise (SME), Motif Bio is not evaluated in this Research Area. It has no antibacterial products on the market.
Access & Stewardship
As a small- to medium-sized enterprise (SME), Motif Bio is not evaluated in this Research Area. It has no antibacterial and/or antifungal products on the market.
* Bacteria and fungi that have been identified as priority R&D targets for limiting AMR, by either the WHO and/or the Centers for Disease Control and Prevention (CDC).